A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Pancreatic Neoplasms
  • Protein Kinase Inhibitors
  • Quinazolines
  • Radiotherapy, Adjuvant

abstract

  • In combination with fixed dose gemcitabine at 40 mg/m(2) twice weekly and radiation at 180 cGy/day, the MTD of erlotinib was found to be 100 mg/day. This is a relatively well tolerated, biologically active combination in a poor prognostic cancer.

publication date

  • January 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdm441

PubMed ID

  • 17878176

Additional Document Info

start page

  • 86

end page

  • 91

volume

  • 19

number

  • 1